Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986285 | 0.93 | CYP2C9 (0.50) | CYP2C9MAPTSMN1; SMN2PTPN5KMT2A | |
| SCHEMBL1560417 | 0.86 | MAPT (0.54) | CYP2C9MAPTKMT2ATSHRKDM4E | |
| SCHEMBL28315787 | 0.84 | KMT2A (0.52) | CYP2C9MAPTKMT2ANPC1RAB9A | |
| SCHEMBL21269958 | 0.84 | MAPT (0.52) | CYP2C9MAPTKMT2ATSHRKDM4E | |
| SCHEMBL21269860 | 0.84 | MAPT (0.52) | CYP2C9MAPTKMT2ATSHRKDM4E | |
| SCHEMBL28314292 | 0.84 | MAPT (0.52) | CYP2C9MAPTKMT2ATSHRKDM4E | |
| SCHEMBL21269891 | 0.84 | MAPT (0.52) | CYP2C9MAPTKMT2ATSHRKDM4E | |
| SCHEMBL28315718 | 0.84 | MAPT (0.52) | CYP2C9MAPTKMT2ATSHRKDM4E | |
| SCHEMBL1679690 | 0.83 | CYP2C9 (0.61) | CYP2C9MAPTSMN1; SMN2PTPN5KMT2A | |
| SCHEMBL28315679 | 0.82 | MAPT (0.50) | CYP2C9MAPTKMT2ATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-6548667-B2 | For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-04-15 | — | — | US | disclosed |
| EP-1208092-A4 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO LTD (KR) | 2003-01-02 | — | — | EP | disclosed |
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
| EP-1208092-A1 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001077092-A1 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | MMP9, MMP3, MMP14 | CYP2C9 874/4885MAPT 4046/4885SMN1; SMN2 654/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | CYP2C9 1196/4885MAPT 2813/4885SMN1; SMN2 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.